A Review of Integrative Medicine in Gynaecological Oncology

Evidenz Integrativer Medizin in der gynäkologischen Onkologie – Review

Abstract

In recent years complementary and alternative medicine (CAM) has increasingly been the focus of international research. Numerous subsidised trials (7903) and systematic reviews (651) have been published, and the evidence is starting to be integrated into treatment guidelines. However, due to insufficient evidence and/or insufficient good quality evidence, this has mostly not translated to practice recommendations in reviews by the Cochrane collaboration gynaecology group. There is nevertheless a not insignificant number of CAM providers and users. The percentage of oncology patients who use CAM varies between 5 and 90%. Doctors have been identified as the main providers of CAM. Half of gynaecologists offer CAM because of personal conviction or on suggestion from colleagues. This must be viewed in a critical light, since CAM is mostly practiced without appropriate training, often without sufficient evidence for a given method – and where evidence exists, practice guidelines are lacking – and lack of safety or efficacy testing. The combination of patient demand and lucratively for doctors/alternative medicine practitioners, both based on supposed effectiveness CAM, often leads to its indiscriminate use with uncertain outcomes and significant cost for patients. On the other hand there is published, positive level I evidence for a number of CAM treatment forms. The aim of this article is therefore to review the available evidence for CAM in gynaecological oncology practice. The continued need for research is highlighted, as is the need to integrate practices supported by good evidence into conventional gynaecological oncology.

Zusammenfassung


Kalder M et al. A Review of... Geburtsh Frauenheilk 2016; 76: 150–155
Introduction

The term “integrative medicine” has become increasingly established in both Anglo-American and German-speaking countries. It implies integration of scientifically tested complementary medicine practices into established evidence-based medicine. The following quotes from the literature from 2006 and 2012 illustrate the term: “Over time, some complementary therapies are proven safe and effective. These become integrated into mainstream care producing integrative oncology, a synthesis of the best of mainstream cancer treatment and rational, data-based, adjunctive complementary therapies” [1]. “Integrative oncology combines the best practices of conventional and complementary oncology, uniting them in one, holistic concept. With the awareness that the two therapeutic methods may occasionally interfere with each other, the best solution is aimed at” [2].

According to the Working Group for Integrative Medicine (AGIMed), integrative medicine should identify practices in the complementary and alternative medicine spectrum (CAM) that are supported by good evidence from convincing studies, and that seem suited to expand the conventional medical portfolio [3]. The Gynaecological Oncology Working Group (AGO) guidelines on breast cancer treatment have integrated complimentary practices since 2002 and have contained a chapter evaluating CAM since 2011 [4]. The current AGO recommendations make a clear distinction between integrative oncology and unconventional practices. Unconventional practices are considered maverick whereas integrative oncology is understood as ancillary or alternative to scientifically based medicine [4]. Complementary practices are seen as experienced-based additions to scientific, evidence-based medicine [5].

Since its establishment in 1937, the USAs National Cancer Institute (NCI) has been requisitioned to evaluate the various CAM methods in the treatment of cancer patients. Studies published in the 1970s and 1980s with negative results contributed to the impression being made that the NCI was intent only on proving a lack of effect of CAM [6]. In 1999 and 2000 White, the former director of the Office of Cancer Complementary and Alternative Medicine (OCCAM) at the NCI, conducted 4 surveys finding that 9 to 91% of American tumour patients used CAM after diagnosis [7]. A 1998 European survey found that between 20 and 70% of the population used CAM [8]. This review presents the evidence from four subareas of CAM research. We describe the CAM practices on offer as well as the demand for CAM in gynaecological oncology, country-specific CAM practice, the evidence of efficacy, safety and interactions, as well as the spectrum of CAM publications and research funding.

CAM Users and Providers in Gynaecological Oncology

In the late 1990s studies were published in Switzerland evaluating the motivation and expectations of CAM users [9]. Oncology patients form a large group of CAM users. Since the 1990s 40–70% of all oncology patients in Germany have used CAM, the emphasis being mostly on the complementary components of CAM, i.e. parallel to conventional treatment [10,11]. Oncology patients who use CAM experience a substantial individual psychological advantage, which can be considered the main motivation for its use [9]. These results agree with findings in the USA. One exception is the wider range quoted in the English literature, with CAM user rates among oncology patients between 5 and 90% [6,11]. It is somewhat alarming that the recommendation to use CAM comes from a friend in 56% of cases, from family members in 29% and from doctors in only 1% [12]. Reasons given by patients for using CAM include consciously fighting against the cancer, physical and psychological support for the body and general well-being. In addition, 23% of those interviewed stated in an alarmingly uncritical way with respect to CAM: “might help – won’t hurt” [12].

Results of a survey conducted in 11 European countries in 2006 among women with breast cancer demonstrated that 45% of patients are CAM users from the time of diagnosis, and that the majority are satisfied with it. According to their own claims only 6.5% of these women did not benefit from using CAM. Young educated women were especially well represented among satisfied CAM users [13]. According to Gross et al. young women with higher education level who have metastatic breast cancer are more likely to seek out alternative medicine practitioners, and use phytotherapy more often, than older, less well educated women [13,14]. There were equal numbers of educated and uneducated women among patients with breast cancer who practiced yoga; these women had a lower Body Mass Index (BMI) [15]. Swisher et al. list previous CAM use (before cancer diagnosis), gynaecological tumour other than cervical carcinoma and annual income over $30 000 as important predictors of CAM use among patients with gynaecological tumours [16].

In the late 1990s, concurrent with studies on CAM users, first publications on the attitudes of doctors appeared describing their characteristics and opinions on the use of CAM in oncology. It was shown that doctors form the main group of practitioners offering CAM to oncology patients, not alternative health practitioners as was assumed [17–20].

Studies from different countries show that doctor's attitudes and opinions vary significantly according to nationality [10,21]. As an example, oncologists in China and Taiwan recommended a combination of CAM and conventional treatment to patients with curable disease less commonly than oncologists in the USA. This finding is surprising in view of the long, nationally-based, cultural and historical CAM traditions in Asia, and since the prevalence of CAM use among tumour patients in this study was over 80% [22].

In Australia, doctors working in the field of oncology rehabilitation refer 84% of patients for CAM [23]. The requirement is therefore understandable that oncologists should be aware of potential interactions between standard prescribed treatment regimes and the CAM products patients use independently [14].

47 to 85% of women with breast cancer who used CAM did not disclose this to their treating doctors [24]. In the field of general gynaecology only 51.8% of women disclosed their use of CAM [11,25]. A logical recommendation is therefore for doctors to destigmatise the use of CAM in their communication with patients [24].

Doctors should ask patients specifically about CAM usage and provide information on potential interactions, risks and the benefits of CAM practices. In this way the communication barrier be-
International Spectrum of Common CAM Practices

The spectrum of CAM implementation in gynaecological oncology is heterogenous. In the 1990s the 6 most common CAM practices described by doctors working in gynaeco-oncology in Germany were mistletoe, homeopathy, acupuncture, selenium substitution, vitamins and diets [27]. Homeopathy was identified as the most commonly used in paediatric oncology (Germany) [28]. Preferred CAM practice differed significantly between studies from different countries [10,21,29,30]. Specific CAM practices are often chosen based on their cultural background. Supokun et al. and their working group in Thailand identified Buddhist prayer (over 90%), phytotherapy (40%) and physical exercises (37%) as the 3 most common CAM practices among gynaecological tumour patients [31]. Women in Turkey with metastatic breast cancer most commonly use phytotherapy followed by dietary supplements [32].

In the field of rehabilitative medicine, which is often the point of initial follow-on treatment for oncology patients, the prescription of certain CAM methods is also common. The Australian study by Mak et al. lists acupuncture (80%), yoga (70%) and Tai Chi (72%) as the most common [15,23]. Fasching et al. report that in Germany 50% of breast cancer patients and 44% of patients with gynaecological tumours in general use CAM. Mistletoe is used most commonly (77%), and more often by breast cancer patients than those with other gynaecological tumours (74.4 vs. 67%). Users of CAM report deterioration in their health less often (35.1 vs. 50.1%) [33]. Older surveys have shown that preferences for CAM vary immensely even within medical specialities [34].

CAM is sometimes recommended on the basis of supposed or confirmed evidence for a specific treatment, sometimes however because conventional therapy has failed. In this respect it is interesting to note that half of gynaecologists who prescribe or recommend CAM do so on the basis of personal conviction or following the advice of a colleague, the conviction however often being based on supposed efficacy, not evidence [17,35]. On the other hand 40% of interviewees recommended CAM because of the ineffectiveness of conventional therapies [27]; in view of the fact that older, more experienced gynaecological oncologists have been identified as the main practitioners offering CAM, this is presumably an expression of helplessness when reaching the limits of conventional treatment options. The recommendation to use CAM could be interpreted as an act of desperation. In our view, however, CAM should be avoided when desperation is the only motivation for its use, since in recent years increasingly helpful palliative medical options have been developed especially in the field of oncology [36].

Efficacy, Safety and Interactions

There is very good evidence for the efficacy of sport/physical activity and nutrition in oncology. Pierce et al. demonstrated a 50% reduction in 10-year breast cancer mortality with a regular diet of fruit and vegetables (at least 5 portions or more distributed over the day) and sport/physical activity (approx. 30 minutes walking 6 days a week). This result was independent of BMI and was not achieved with either healthy diet or physical activity alone [37]. Despite increased scientific study there is nevertheless a lack of evidence proving efficacy of CAM practices and their safety for patients. Numerous publications point out this lack of evidence, the authors unanimously calling for further studies to provide evidence of safety and indication-based efficacy of the individual CAM treatments [38].

As an example, the systematic review by Bardia et al. concludes that there is a lack of multicentre studies evaluating the effects of CAM on alleviating tumour-related pain. The studies included in the review do show positive trends for some CAM practices, particularly hypnosis and acupuncture, however the level of evidence does not support any general recommendations. Prospective, randomised, multicentre trials are required whose primary endpoints are the efficacy of CAM treatments [39].

A literature search from 2010 found no evidence for efficacy or safety of herbal treatments for hot flushes among women with previous breast cancer. The use of phytooestrogen containing soya products for women with previous breast cancer is explicitly not recommended in the face of evidence of a counterproductive effect, i.e. that phytooestrogens may increase the likelihood of tumour recurrence [40].

Another relevant aspect is the research pertaining to the interference between standard treatments and alternative components of CAM. Han et al. followed breast cancer patients over a period of 10 years who had declined or delayed standard therapy in favour of alternative treatment. A substantial increase in disease progression, recurrence risk and mortality was observed. The estimated 10 year survival rate calculated in this study for patients with FIGO stage II cancer, who declined an operation, was 69.5%. Actual survival at a median of 33 months follow-up was only 36.4%. The 61 patients were on average in FIGO stage II on study inclusion, compared to FIGO IV following their alternative treatments. Han et al. recommended that these data be integrated into doctor-patient discussions, to support decision-making for individual treatments [41].

The literature contains published evidence of numerous interactions and dangers associated with CAM. Whereas earlier publications reported reactions such as fever and severe anaphylaxis/circulatory shock following mistletoe injection, current studies show no evidence of serious events [42,43]. A measureable improvement in quality of life has been shown for breast cancer patients on chemotherapy who received mistletoe preparations, however evidence for an effect of mistletoe on survival, local tumour control and reduction in the side-effects of antitumour treatments was regarded overall as weak [43].

Due to interaction with oncology drugs CAM preparations can cause increased toxicity and reduced efficacy of standard oncological treatment. The phytotherapeutic agent St. John’s wort, known in the treatment of depression, interacts with the cytochrome P450 isoform CYP3A4, amongst others, thus reducing the chemotherapeutically active metabolite of irinotecan by over 50%. Patients treated with St. John’s wort thus show a counterproductive improved tolerance of their chemotherapy through reduction in toxicity [44].

There is level 1 evidence for “mindfulness-based stress reduction training” (MBSR) for the treatment of anxiety disorders and depression in oncology patients with diverse tumours, without any of the above mentioned interactions [45,46]. MBSR can reduce stress-related physical and psychological symptoms (anxi-
Inhibit the proliferation of leiomyoma cells, both in vitro and in vivo for HPV positive patients with cervical lesions [63]. Zhang et al. reported successful treatment of cervical lesions with green tea extracts and suggest a potential treatment for HPV positive patients with cervical lesions [63]. Zhang et al. were able to demonstrate that green tea extracts effectively inhibit the proliferation of leiomyoma cells, both in vitro and in vivo [64]. Kim et al. and research group recorded an inhibitory effect of green tea polyphenol epifallocatechin 3 gallate on ovarian carcinoma cell lines, which may be relevant for future drug development for ovarian cancer [65]. Kakuta et al. concluded that green tea consumption is associated with decreased risk for the development of uterine corpus endometrioid adenocarcinoma [66].

Longo et al. showed that fasting two days before and one day after chemotherapy reduces treatment side effects. Healthy cells seem to react self-protectively by inhibition of their cell cycle on fasting days, thus sparing themselves the effects of the antitumour therapy. Tumour cells on the other hand lack this adaptability, their proliferative state making them vulnerable to antitumour treatment. In addition, quicker recovery of the blood cell population was observed with fasting [67–69]. The fear of weight loss while on chemotherapy is a factor that must be considered; treatment with fasting does not seem to be a method of choice, and should at the very least be evaluated in the study setting with consideration of BMI. A current Cochrane review, fresh off the press from November 2015, describes a possible beneficial effect of cannabis-based therapy for chemotherapy induced vomiting. The authors describe the available literature on the subject (23 RCTs) as very limited [70].

**Table 1** Observation of the increase of publications, reviews and RCTs at the example of acupuncture and homeopathy.

<table>
<thead>
<tr>
<th></th>
<th>1900–1999</th>
<th>2000–2011</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acupuncture</strong></td>
<td>Publications</td>
<td>Reviews</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td>7553</td>
<td>576</td>
<td>321</td>
</tr>
<tr>
<td><strong>Homeopathy</strong></td>
<td>2223</td>
<td>132</td>
<td>49</td>
</tr>
</tbody>
</table>

**Number of CAM Publications and Funding**

A comparison of the time intervals before 1999 and between 2000 and 2011 on MEDLINE reveals an abrupt increase in CAM publications (e.g. on acupuncture and homeopathy), the increase is however accounted for by randomised controlled trials and review articles (Table 1).

The results of intensive research efforts (up until 30.11.2015) financed by the NCCAM include 7903 published studies (78 gynaecological and 145 oncological) and 651 reviews (7 gynaecological and 23 oncological), as well as 37 systematic reviews by the Cochrane collaboration on various topics in oncology (3 on breast cancer and one on colposcopy in the context of early screening) [71]. There are however few positive recommendations and the majority of Cochrane reviews on CAM in the field of gynaecology reveal questionable evidence from which no practice recommendations can be drawn [38].

The National Institute of Health (NIH) in the USA has increased its funding of CAM research incrementally from 116000 $ in 1999 to 124296000 $ in 2014, however the amount from 2014 represents only 0.41% of NIHs total budget for 2014 (30142653000 $). In comparison the NCI received a budget of 4923238000 $ (16.3%) for 2014 [72].

---

Kaldner M et al. A Review of... Geburtsh Frauenheilk 2016; 76: 150–155
Future Perspective

The economic situation in the health sector and the increased demand for CAM treatment from patients in gynaecological oncology constitute significant impulses in the continuing development of evidence-based data in this medical field in Germany. Doctors have an ethical obligation to optimise the use of resources, implementing newly acquired evidence through the integration of evidence-based CAM into conventional medicine, and counselling patients proactively about non-evidence-based practices.

Conflict of Interest

None.

Affiliations
1 Klinik für Frauenheilkunde und Geburtshilfe, Philipps-Universität Marburg, Marburg
2 AGAPELION Markus Krankenhaus, Abteilung für Gynäkologie und Geburtshilfe, Frankfurt am Main
3 Klinik für Gynäkologie und Geburtshilfe, Klinikum Ernst von Bergmann, Potsdam
4 Frauenklinik, Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe
5 Zentrum für Frauenheilkunde, Klinikum Bielefeld Mitte, Bielefeld
6 Universitäts-Brustzentrum Frankfurt, Frauenklinik des Universitätsklinikums Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen – Europäische Metropolregion Nürnberg, Nürnberg
7 Universitätsklinik für Frauenheilkunde und Geburtshilfe, Paracelsus Medizinische Privatuniversität, Nürnberg
8 Frauenklinik und Brustzentrum Nathansift, Klinikum Fürth, Fürth
9 Klinik und Poliklinik für Geburtshilfe und Frauenkrankheiten, Universitätsmedizin Mainz, Mainz
10 Frauenklinik des Klinikums rechts der Isar, Technische Universität München, München
11 Praxis für Frauenheilkunde, Geburtshilfe und Naturheilkunde, Rodgau
12 Universitätsfrauenklinik, Universitätsklinikum Heidelberg, Heidelberg
13 Brustzentrum und Klinik für Sonologie der Kliniken Essen-Mitte, Essen

References
6 White JD. The National Cancer Institute’s perspective and agenda for promoting awareness and research on alternative therapies for cancer. J Altern Complement Med 2002; 8: 545–550
8 Jonas W. Alternative medicine and the conventional practitioner. JAMA 1998; 279: 708–709
16 Swisher EM, Cohn DE, Goff BA et al. Use of complementary and alternative medicine among women with gynaecologic cancers. Gynecol Oncol 2002; 84: 363–367
17 Bourgeault IL. Physicians’ attitudes toward patients’ use of alternative cancer therapies. CMAJ 1996; 155: 1679–1685
18 Crocetti E, Crotti N, Montella M et al. Complementary medicine and oncologists’ attitudes: a survey in Italy. Tumori 1996; 82: 539–542
26 Richardson MA, Masse LC, Nancy K et al. Discrepancy views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer 2004; 12: 797–804

Kalder M et al. A Review of... Geburtsh Frauenheilk 2016; 76: 150–155


The path from avant garde to mainstream. Forsch Komplementmed 2013; 20: 10–22


Cardiac tamponade following acupuncture. Chest 2000; 118: 673–674


A Review of 20 years Research Complementary Medicine: the path from avant garde to mainstream. Forsch Komplementmed 2013; 20: 10–12

Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 2012; 4: 124ra27

Stabilization of cancer is a significant clinical endpoint of integrative therapy: a randomized controlled trial. J Clin Oncol 2010; 28: 634–640


Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; 7: CD009464


Cardiac tamponade following acupuncture. Chest 2000; 118: 673–674


Cardiac tamponade following acupuncture. Chest 2000; 118: 673–674